Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The <keyword id="23195354" type="General" weightage="100" keywordseo="COVID-XEC" source="keywords">COVID XEC</keyword> variant has recently gained attention due to its <keyword id="23204106" type="General" weightage="20" keywordseo="rapid-spread" source="keywords">rapid spread</keyword> across Europe and concerns that it might soon become dominant. First identified in Germany in June 2024, the variant has since been detected in over a dozen countries, including the UK and the US. As with other variants of <keyword id="20249557" type="General" weightage="20" keywordseo="SARS-CoV-2" source="keywords">SARS-CoV-2</keyword>, <keyword id="23204107" type="General" weightage="20" keywordseo="xec" source="keywords">XEC</keyword> is a subvariant of <keyword id="19895062" type="General" weightage="20" keywordseo="omicron" source="keywords">Omicron</keyword>, and the symptoms of the disease caused by the KP.3 lineage virus largely mirror those of previous strains, including fever, cough, sore throat, headaches, and muscle aches.<br /><h2>Is XEC more dangerous?</h2>Although the XEC has shown signs of being more contagious than other recent variants, experts do not believe it poses a greater risk of severe disease for most people. Dr Eric Topol, a leading voice in COVID research, suggests that while XEC may soon outcompete other subvariants due to its <keyword id="20551797" type="General" weightage="20" keywordseo="transmissibility" source="keywords">transmissibility</keyword>, <keyword id="23043733" type="General" weightage="20" keywordseo="existing-vaccines" source="keywords">existing vaccines</keyword> should still offer protection. This is because XEC remains an <keyword id="19919614" type="General" weightage="20" keywordseo="Omicron-subvariant" source="keywords">Omicron subvariant</keyword>, meaning it shares enough genetic similarity for current vaccines to be effective.<br /><h2>Should you be worried?</h2>While XEC is spreading, experts emphasise that its arrival doesn’t signal a drastic shift in the COVID landscape. It’s not a new strain requiring another Greek letter designation, and it hasn't been shown to cause more severe disease compared to other Omicron subvariants. However, with colder months approaching in the Northern Hemisphere, where <keyword id="20163355" type="General" weightage="20" keywordseo="respiratory-infections" source="keywords">respiratory infections</keyword> typically increase, XEC’s impact might be more noticeable.<br /><div type="Article" hostid="261" msid="113246996" title="Mpox outbreak: Understand what your insurance covers for Mpox treatment" mstype="2" mssubtype="0"></div>While the new COVID XEC has begun to rapidly spread across Europe, North America, and some parts of Asia, fortunately, there have not yet been confirmed reports of the variant reaching India.<br /><br />To reduce your risk, it's essential to stay up to date with vaccinations, practise good hygiene, and remain vigilant, especially in crowded or poorly ventilated spaces. While we’re no longer in the early stages of the pandemic, <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">COVID-19</keyword> remains unpredictable, and experts continue to monitor variants like XEC closely.<br />

COVID XEC: Should you worry about the new fast-spreading Omicron subvariant?

After years of intensified focus on <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">COVID-19</keyword>, <keyword id="19992404" type="General" weightage="100" keywordseo="Tuberculosis" source="keywords">tuberculosis</keyword> (TB) has once again emerged as the leading <keyword id="20564668" type="General" weightage="20" keywordseo="infectious-disease" source="keywords">infectious disease</keyword> killer worldwide. This resurgence is a sobering reminder that despite our pandemic response, TB has continued to claim lives, especially in low- and middle-income countries (LMICs), where resources are often stretched thin.<br /><br />According to the latest <keyword id="19896311" type="General" weightage="20" keywordseo="World-Health-Organization" source="keywords" meta.keywordsubtype="org" meta.entityname="World Health Organization" meta.hostid="261" meta.entityid="World Health Organization">World Health Organization</keyword> (<keyword id="19895006" type="General" weightage="20" keywordseo="WHO" source="keywords">WHO</keyword>) report, approximately 8.2 million people were diagnosed with TB in 2023, marking the highest number of cases recorded since global monitoring began in 1995.<br /><h2><keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword> and Indonesia</h2>The recent spike in TB cases is largely driven by increases in two countries — India and Indonesia. Together, they accounted for 45% of the global rebound in TB diagnoses between 2021 and 2023, underscoring their critical role in the worldwide fight against TB. Three other countries, the Philippines, Nigeria, and Pakistan, also made significant contributions, collectively accounting for another 32% of the increase. This means that more than three-quarters of the global resurgence in TB can be traced to these five countries alone.<br /><br />One key reason for these increases is the “backlog” effect created by COVID-19 disruptions. During the pandemic, healthcare systems in many countries, including India and Indonesia, had to shift focus to COVID-19, which delayed TB diagnosis and treatment. In 2023, as these countries ramped up recovery efforts, many previously undetected TB cases surfaced, creating an apparent spike in reported numbers. This trend highlights the importance of sustainable healthcare infrastructure capable of handling simultaneous health crises.<br /><h2>Gaps in TB case detection</h2>Despite the daunting increase in TB cases, some countries have made notable progress in <keyword id="23741990" type="General" weightage="20" keywordseo="treatment-coverage" source="keywords">treatment coverage</keyword>. Among the 30 high-burden TB countries, those with the highest levels of treatment coverage in 2023 included Brazil, India, Mozambique, Papua New Guinea, Sierra Leone, Uganda, and Zambia, with coverage rates surpassing 80%. India’s <keyword id="21052657" type="General" weightage="20" keywordseo="national-tuberculosis-elimination-program" source="keywords">National Tuberculosis Elimination Program</keyword> (NTEP) has undoubtedly played a pivotal role in this, aiming to eradicate TB by 2025 — five years ahead of the global target. By focusing on expanded testing, improved diagnostic tools, and more accessible treatment options, India has achieved high treatment coverage levels despite the challenges.<br />    <div type="Article" hostid="261" msid="114732986" title="Air Quality Alert: Nearly 30% of asthma cases tied to fine particulate matter exposure from bad air" mstype="2" mssubtype="0"></div>However, a significant treatment gap remains. The difference between estimated TB incidence and actual diagnoses still affects millions, especially in countries with large populations like India, Indonesia, Pakistan, China, and Myanmar. These five nations together account for about 50% of the global gap in reported TB cases, with India alone responsible for 16% of the discrepancy.<br /><h2>India’s unique position in the global TB fight</h2>As the nation with the largest share of global TB cases, India has a unique and critical responsibility in addressing the disease. The high TB burden in India is tied to several factors, including undernutrition, poverty, and limited access to healthcare in rural areas. Moreover, with 26% of all TB cases globally, India’s battle against TB will significantly impact the global fight. The government’s financial support for TB-affected households also aims to reduce the economic burden of treatment.<br /><br />However, challenges remain, especially with <keyword id="22004277" type="General" weightage="20" keywordseo="multidrug-resistant-TB" source="keywords">multidrug-resistant TB</keyword> (MDR/RR-TB). While treatment success rates for MDR/RR-TB have reached 68%, diagnosing and treating all drug-resistant cases is an ongoing challenge. In 2023, India’s coverage of preventive treatment for TB among people living with HIV and close contacts of TB patients also saw improvements, but underfunding continues to limit the full scope of TB elimination efforts.<br /><h2>Global funding gaps</h2>Global funding shortages for <keyword id="21039793" type="General" weightage="20" keywordseo="TB-prevention" source="keywords">TB prevention</keyword> and treatment are a significant hindrance to progress. Only $5.7 billion of the targeted $22 billion in funding was met in 2023, and for LMICs — where nearly all of the TB burden lies — the available funding falls well short of their needs. The United States remains the largest bilateral donor, and contributions from the Global Fund to Fight AIDS, Tuberculosis, and Malaria are crucial. However, these funds are not enough to meet essential TB service requirements, leaving healthcare systems under-resourced.<br />    <div type="Article" hostid="261" msid="114646545" title="Doctors struggle to treat long Covid patients in India; researchers point to inadequate studies" mstype="2" mssubtype="0"></div>Even in 2022, only one-fifth of the $5 billion target for research funding was achieved, as per the report. This underfunding hampers the development of improved diagnostics, drugs, and vaccines, which are crucial to TB prevention and treatment. <br /><br />Moreover, many of the drivers of TB are related to social factors, such as undernutrition, smoking, alcohol use, and diabetes, making it imperative to address these root causes. For instance, almost half of the TB-affected households globally face what the WHO calls "catastrophic costs" in seeking treatment. This burden is particularly severe in India, where low-income families often forgo treatment due to financial constraints.<br /><br />As WHO’s Director-General Dr Tedros Adhanom Ghebreyesus puts it, "The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it, and treat it.”<br /><br />The WHO’s Global tuberculosis report 2024 can be accessed <a href="https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024">here</a>.<br />

Tuberculosis dethrones COVID-19 as world’s top infectious killer again; Half of all new cases from India, Indonesia

In the last two years, there has been a rapid rise in scams in India and a lot of people have lost their hard-earned money after trusting strangers for financial advice. Be it a fraudulent app, being added to a shady WhatsApp group, or receiving phone calls from strangers that sound too good to be true, many cases have come to light. Now, in a new incident, a doctor from Thane, Maharashtra, was misled by three Karnataka-based suspects who promised earnings via a municipal contract to supply medical equipment, costing him ₹3.84 crore. Despite investing over a three-year period, he saw no returns and reported the crime to the Naupada police, who have registered a case but made no arrests.<br /><br /><b>Thane doctor tricked by false municipal contract</b><br /><br />According to a PTI report, a 39-year-old doctor in Thane, Maharashtra was deceived by three men from Karnataka. These fraudsters offered him lucrative returns through a supposed municipal contract for supplying medical equipment. Convinced by the promise of reliable profits, the doctor began investing heavily in December 2020, making significant contributions until March this year.<br /><br />The doctor’s substantial investment – totalling ₹3.84 crore – was made over multiple transactions from December 2020 and March this year, in anticipation of high returns that never materialised. Suspicion finally arose after the doctor had seen no profits despite his repeated investments. Recognising he may have been defrauded, he reached out to the Naupada police station, who registered a case under charges of cheating. While no arrests have been made so far, authorities have launched an investigation to track down the perpetrators and recover the funds if possible.<br /><br />A police official told PTI, "The man approached police after he did not get profits or any return on investment. We have registered a case of cheating but have not arrested anyone."<br /><br /><b>Ahmedabad gynaecologist duped in <keyword id="21361161" type="General" weightage="100" keywordseo="stock-market-scam" source="keywords">stock market scam</keyword></b><br /><br /><br />In a similar incident, a gynaecologist from Ahmedabad lost ₹1.1 crore to a scam that began with a social media advertisement. Attracted by the potential for substantial stock market returns, the doctor engaged with a group promising expert tips and was subsequently added to a WhatsApp group where members shared investment insights. Through this group, he was introduced to a web link for stock and IPO investments, along with an application that required his banking details and identification documents.<br /><br />A PTI report revealed that the doctor’s initial investment of ₹50,000 yielded a profit of ₹10,000, which he successfully withdrew. This initial success encouraged him to make larger investments, transferring ₹1.1 crore through multiple transactions in pursuit of higher gains. <br /><br />When he later attempted to withdraw his funds, he was unexpectedly asked to pay 20% of his total profits. After refusing this demand, he was removed from the WhatsApp group and realised the extent of the deception. He contacted Cybercrime police in February, and after months of waiting, a formal case was registered against unknown suspects under charges of breach of trust and cheating, alongside provisions of the <keyword id="20003647" type="General" weightage="20" keywordseo="information-technology-act" source="keywords">Information Technology Act</keyword>.

Thane doctor gets cheated of ₹3.84 crore, was promised high financial returns by 3 men

Imagine taking a deep breath, expecting fresh, clean air, but instead, inhaling particles so tiny they’re invisible but powerful enough to change your life. For millions worldwide, that’s the reality — and it’s taking a toll on their lungs. A new global study shows that nearly 30% of <keyword id="22476122" type="General" weightage="100" keywordseo="asthma-cases" source="keywords">asthma cases</keyword> can be traced back to long-term exposure to <keyword id="20147117" type="General" weightage="20" keywordseo="fine-particulate-matter" source="keywords">fine particulate matter</keyword>, or <keyword id="20573061" type="General" weightage="20" keywordseo="PM2-5" source="keywords">PM2.5</keyword>, the kind of pollution that often comes from cars, factories, and even cooking fires.<br /><h2>How PM2.5 impacts asthma</h2>Asthma is a chronic respiratory condition characterised by recurring symptoms like wheezing, coughing, and difficulty breathing. While the exact causes of asthma remain complex and varied, this new study underlines that PM2.5 pollution is a significant risk factor.<br /><br />The study brings together insights from 68 epidemiological studies conducted across 22 countries, spanning regions from North America to South Asia. This comprehensive meta-analysis demonstrates the consistent impact of PM2.5 on asthma development.<br />    <div type="Article" hostid="261" msid="114504550" title="Most people miss THIS warning on their mosquito repellent vaporizer’s label" mstype="2" mssubtype="0"></div>Lead author Dr Ruijing Ni explained, “We estimate that globally in 2019, almost a third of asthma cases are attributable to long-term PM2.5 exposure, corresponding to 63.5 million existing cases and 11.4 million new cases.”<br /><h2>The Indian asthma problem</h2>India, one of the world’s most polluted countries, faces a particularly severe burden from <keyword id="19900550" type="General" weightage="20" keywordseo="air-pollution" source="keywords">air pollution</keyword>. Studies have shown that PM2.5 levels in many Indian cities far exceed the <keyword id="19896311" type="General" weightage="20" keywordseo="World-Health-Organization" source="keywords" meta.keywordsubtype="org" meta.entityname="World Health Organization" meta.hostid="261" meta.entityid="World Health Organization">World Health Organization</keyword>'s safe limit of 5 µg/m³. This exposure is especially dangerous for children, whose lungs and immune systems are still developing.<br /><br />The numbers are worrying: around 15-20 million Indians suffer from asthma, making up a significant portion of the estimated 339 million cases worldwide. Children are disproportionately affected; a 2019 report indicated that approximately 6% of children aged 1 to 5 in India show asthma symptoms. This exposure often results in airway inflammation and oxidative stress, which increases vulnerability to <keyword id="19923193" type="General" weightage="20" keywordseo="respiratory-diseases" source="keywords">respiratory diseases</keyword>.<br /><h2>What the data says</h2>The research team employed exposure-response curves to better understand the link between PM2.5 levels and asthma cases. By considering data from both high-income and low- and middle-income countries, the researchers could provide a more accurate global assessment of PM2.5’s <keyword id="21037424" type="General" weightage="20" keywordseo="health-impact" source="keywords">health impact</keyword>.<br /><br />The study found that in Germany, for instance, PM2.5 may be responsible for about 11% of new asthma cases — roughly 28,000 people. However, the burden is even higher in low- and middle-income countries like India, where higher levels of pollution are coupled with limited healthcare access. This disparity highlights the need for global action to reduce PM2.5 emissions, especially in regions where pollution levels and health impacts are most severe.<br /><h2>Policy implications and recommendations</h2>The findings have clear implications for policymakers. Strengthening <keyword id="19918941" type="General" weightage="20" keywordseo="air-quality" source="keywords">air quality</keyword> regulations, especially in high-exposure regions, could prevent millions of new asthma cases and reduce healthcare costs.<br /><br />“Our findings highlight the urgent need for policymakers to enforce stringent legislation to continuously combat air pollution,” emphasised another study author Prof. Yafang Cheng. <br />    <div type="Article" hostid="261" msid="114695519" title="Are your green firecrackers really ‘green? Here’s all you need to know before doing your Diwali shopping" mstype="2" mssubtype="0"></div>In addition to governmental measures, personal protective actions like wearing masks and installing air purifiers in homes can also help individuals reduce their exposure to PM2.5, particularly during high-pollution periods.<br /><br />This study adds to the growing evidence that reducing air pollution is critical for public health. While global challenges like PM2.5 pollution may seem daunting, each step toward cleaner air can bring significant health benefits. For countries like India, where asthma rates and pollution levels are both alarmingly high, these findings underscore an urgent need for both policy and community action to protect the most vulnerable — particularly children.<br />

You Searched For "new omicron cases in india" and got 4 results

COVID XEC: Should you worry about the new fast-spreading Omicron subvariant?

BI India Bureau

Tuberculosis dethrones COVID-19 as world’s top infectious killer again; Half of all new cases from India, Indonesia

Ankush Banerjee

Thane doctor gets cheated of ₹3.84 crore, was promised high financial returns by 3 men

Divyanshi Sharma

Air Quality Alert: Nearly 30% of asthma cases tied to fine particulate matter exposure from bad air

BI India Bureau

Popular Keywords

Buying Guides